What is trophon2 2020
Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant, a proprietary disinfectant liquid; trophon chemical indicators; trophon AcuTrace operator cards, medical instrument tags, printers, printer USB cables, printer label rolls, and logbooks; trophon wall mounts, printer wall mounts, carts, and printer cart mounts; trophon companion drying wipes and companion wipes wall mounts; clean ultrasound probe covers; and trophon AcuTrace PLUS activation cards. Nanosonics General Information Description.
Home; About Us. While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person Now, with the release of trophon2, Nanosonics has gone even further in providing the most advanced ultrasound high level disinfection solution in the world, offering: Nanosonics’ Story; Board of Directors; Executive team; North American team; International Management team; Products.
Pay is salary, bonuses, etc. This information is to be used for personal, non-commercial purposes only. Principal activities During the year, the principal activities of the Group consisted of: At midday on Friday, it was down about 6.5 per cent at $6.58, amid a broader sell-off.The company is led by Michael Kavanagh, who joined in 2013, having previously spent a decade at hearing implant maker and Morningstar wide-moat stock The trophon was launched in 2009 and is a pioneer product in preventing infection in healthcare settings. Nanosonics (ASX: NAN) is more than 130 per cent overvalued according to the $2.95 fair value estimate of Morningstar analyst Nicolette Quinn.
Nanosonics (NAN) is a technology driven company that is commercialising innovative and unique customer focused disinfection solutions. It has installed about 20,000 trophon units in an addressable market of about 120,000. ... 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. The company is led by Michael Kavanagh, who joined in 2013, having previously spent a decade at hearing implant maker and Morningstar wide-moat stock Cochlear (ASX: COH). Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia.Discover new investment ideas by accessing unbiased, in-depth investment researchFrankfurt - Frankfurt Delayed Price. Currency in EURAmounts are as of and compensation values are for the last fiscal year ending on that date. Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. Nanosonics was founded in 2001 and listed on the ASX in 2007 at about 77 cents. She expects its 50 per cent market share in the US to reach 80 per cent by the end of the decade. Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. It operates in North America, Europe, the Middle East, and the Asia Pacific. The company manufactures and distributes the trophon ultrasound probe disinfector, and its associated consumables and accessories for reducing cross-contamination between patients and the spread of healthcare acquired infections.